Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

NCT03071406 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma
Skin Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]